SRRT

Across TCGA pan-cancer cohorts, SRRT Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SRRT data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SRRT Mutation is associated with better overall survival. In most high-consensus cancer types, elevated SRRT expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, LUAD, and KICH are the cancer types where SRRT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	II,III,IV	1.000	0.400	.006	36	view →
LUAD	OS	Median	All	0.079	0.788	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	DFS	Median	All	0.896	0.616	.015	4	view →
LIHC	OS	Median	All	0.258	0.773	.018	3	view →
SKCM	DFS	Median	All	0.439	0.740	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SRRT–BLCA (OS)

Open the BLCA breakdown →